Identifying topiramate's therapeutic mechanisms through motivational salience

通过动机显着性识别托吡酯的治疗机制

• 批准号: 8713971
• 负责人: Jason D Robinson
• 金额: $ 19.17万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-01 至 2017-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8713971
• 关键词: Alcohol dependence; Alcohols; Anti-Anxiety Agents; Anticonvulsants; Behavioral; Biological Markers; Cigarette; Clinical; Controlled Clinical Trials; Cues; Data; Dependence; Dopamine; Dose; Drug Addiction; Drug usage; Emotional; Event-Related Potentials; Funding; Glutamate Receptor; Heavy Drinking; Individual; Knowledge; Laboratories; Measures; Mediating; Modeling; Neuraxis; Neurobiology; Nicotine Dependence; Outcome Study; Participant; Pharmaceutical Preparations; Pharmacological Treatment; Placebo Control; Placebos; Process; Property; Psychological reinforcement; Randomized; Recruitment Activity; Relapse; Rewards; Sedation procedure; Site; Smoker; Smoking; Stimulus; Substance Addiction; Therapeutic; Therapeutic Agents; Treatment outcome; University of Texas M D Anderson Cancer Center; Visit; Withdrawal; Work; addiction; alcohol abuse therapy; craving; drug of abuse; drug withdrawal; experience; gamma-Aminobutyric Acid; innovation; neurotransmission; parent grant; prevent; relating to nervous system; sedative; sensor; substance abuse treatment; topiramate

DESCRIPTION (provided by applicant): The anticonvulsive topiramate (TPM) has been successfully used as a therapeutic agent for the treatment of substance abuse, including alcohol and nicotine dependence, but the precise therapeutic mechanisms are unknown. The objective of this proposal is to determine the likely therapeutic mechanism of TPM by using event-related potential (ERP) measures, with participants recruited as part of a currently funded multisite placebo-controlled clinical trial treating alcohol-dependent smokers. As part of the parent grant, participants will be randomized to receive placebo, low-dose TPM (up to 125 mg/day), or high-dose TPM (up to 250 mg/day), along with brief behavioral compliance enhancement treatment, to prevent relapse to smoking and heavy drinking. For this proposal, participants (n=123; parent grant n=78, this proposal n=45) at The University of Texas MD Anderson Cancer Center site will complete two laboratory ERP assessments that coincide with clinical visits at baseline (1 week pre-medication, 6 weeks pre-quit) and pre-quit (5 weeks on medication, 1 week pre-quit). These assessments will consist of dense-array ERPs (129 sensors) recorded during the presentation of pictures with drug-related (alcohol and cigarette cues), emotional (pleasant and unpleasant), and neutral content. The late positive potential (LPP) ERP component will provide us with a central nervous system measure of motivational salience of the pictures. The first specific aim of this study is to identify TPM's therapeutic mechanism by evaluating its impact on the motivational salience of drug-related and emotional cues, and the second aim is to determine which therapeutic mechanism mediates the impact of TPM on post-quit drug use, reinforcement, craving, and withdrawal. The significance and impact of this project are threefold: 1) this will be the first study to evaluate the likely therapeutic mechanisms of TPM in the treatment of alcohol-dependent smokers, 2) the proposed biomarker for identifying therapeutic mechanisms, LPP ERP measures of motivational salience, could be used to identify which alcohol-dependent smokers are likely to benefit from TPM, and 3) this biomarker could be used to identify the likely therapeutic mechanisms of other pharmacological treatments of substance dependence and those who would likely benefit from them. We anticipate that our data will have a positive impact by contributing to the refinement of current models of drug addiction and will fundamentally advance our knowledge of the neurobiological processes involved in nicotine addiction.

描述（由申请方提供）：抗惊厥托吡酯（TPM）已成功用作药物滥用（包括酒精和尼古丁依赖）的治疗药物，但确切的治疗机制尚不清楚。本提案的目的是通过使用事件相关电位（ERP）测量来确定TPM的可能治疗机制，招募参与者作为目前资助的治疗酒精依赖性吸烟者的多地点安慰剂对照临床试验的一部分。作为父母资助的一部分，参与者将随机接受安慰剂、低剂量TPM（高达125 mg/天）或高剂量TPM（高达250 mg/天），沿着简短的行为依从性增强治疗，以防止吸烟和酗酒复发。对于本提案，德克萨斯大学MD安德森癌症中心研究中心的参与者（n=123;父母资助n=78，本提案n=45）将在基线（用药前1周，戒烟前6周）和戒烟前（用药5周，戒烟前1周）完成与临床访视一致的两次实验室ERP评估。这些评估将包括密集阵列ERP（129个传感器），在呈现与药物相关（酒精和香烟线索），情感（愉快和不愉快）和中性内容的图片期间记录。晚期正电位（LPP）的ERP成分将为我们提供一个中枢神经系统的措施，动机的图片的显着性。本研究的第一个具体目的是确定TPM的治疗机制，通过评估其对药物相关和情绪线索的动机显着性的影响，第二个目的是确定哪种治疗机制介导TPM对戒烟后药物使用，强化，渴望和戒断的影响。该项目的意义和影响有三个方面：1）这将是 第一项评估TPM在治疗酒精依赖性吸烟者中的可能治疗机制的研究，2）用于鉴定治疗机制的所提出的生物标志物，动机显著性的LPP ERP测量，可用于鉴定哪些酒精依赖性吸烟者可能受益于TPM，和3）这种生物标志物可用于鉴定物质依赖的其他药物治疗的可能治疗机制，可能从中受益。我们预计，我们的数据将产生积极的影响，有助于完善目前的药物成瘾模型，并将从根本上推进我们对尼古丁成瘾所涉及的神经生物学过程的认识。